Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with Asthma

Award Number: R01AI176171
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2023
PERIOD OF PERFORMANCE END DATE: 01/31/2028

Group Awards By:

View Award Description

Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with Asthma - PROJECT SUMMARY/ABSTRACT In the wake of a global pandemic caused by the ancestral strain of SARS-CoV-2, infections with emerging variant strains are an ongoing cause of morbidity and mortality. Robust respiratory mucosal immune responses to SARS-CoV-2 infection and/or vaccination are vital to prevent re-infection and complications of emerging variant strains. Children with poorly controlled, Th2-mediated asthma treated with high-dose corticosteroids are an important at-risk population for hospitalization with variant strains of SARS-CoV-2, often in association with seasonal respiratory viral co-infections. Although children mount durable systemic adaptive immune responses to SARS-CoV-2 infection and/or vaccination, very little is known as to whether Th2 inflammation present in the lungs of many children with asthma dysregulates the lower respiratory mucosal adaptive immune response to the ancestral virus and its variant strains. Therefore, the broad goal of this proposal is to examine blood and lower respiratory adaptive mucosal immune signatures, including spike (S) and receptor-binding domain (RBD) antibodies, neutralizing antibodies, and T and B cell responses to previous infection with SARS-CoV-2 and variant strains (Specific Aim One) and/or mRNA vaccination (Specific Aim Two) in children with asthma and healthy controls. We will furthermore interrogate significant determinants of humoral and T cell adaptive immune response variables with generalized linear models to identify those determinants which most inform adaptive responses. To further examine mechanisms of allergen-induced inflammation on adaptive immunity to SARS- CoV-2 and variants in the blood and lungs, we will (Specific Aim Three) infect juvenile K18-hACE2 mice sensitized to house dust mite in the presence and absence of corticosteroid treatment and mRNA vaccination. New knowledge from these studies should increase the understanding of adaptive immunity to SARS-CoV-2 infection and/or vaccination in children in a way to advance anti-viral treatment, isolation measures, and development of novel booster vaccines targeting mucosal immunity. We are prepared to accomplish these aims through an established team of investigators with experience in childhood asthma and bronchoscopy, in partnership with immunologists with expertise in the investigation of respiratory mucosal immunity to SARS-CoV- 2 infection and mRNA vaccination.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $648,660 )
2026	2026	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Allergy and Infectious Diseases Research	000	4	1/30/2026	NON-COMPETING CONTINUATION	$648,660
														Subtotal = $648,660

Issue Date FY: 2025 ( Subtotal = $678,376 )
2025	2025	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Allergy and Infectious Diseases Research	000	3	5/16/2025	NON-COMPETING CONTINUATION	$678,376
														Subtotal = $678,376

Issue Date FY: 2024 ( Subtotal = $697,498 )
2024	2024	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Allergy and Infectious Diseases Research	002	2	6/7/2024	NON-COMPETING CONTINUATION	$69,751
2024	2024	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Allergy and Infectious Diseases Research	001	2	4/24/2024	NON-COMPETING CONTINUATION	$0
2024	2024	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Allergy and Infectious Diseases Research	000	2	1/11/2024	NON-COMPETING CONTINUATION	$627,747
														Subtotal = $697,498

Issue Date FY: 2023 ( Subtotal = $707,188 )
2023	2023	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 N EMMET ST	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Allergy and Infectious Diseases Research	000	1	2/1/2023	NEW	$707,188
														Subtotal = $707,188

Grand Total All Awards = $2,731,722

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with Asthma

Award Number: R01AI176171

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2023

PERIOD OF PERFORMANCE END DATE: 01/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer